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a b s t r a c t 
Mucopolysaccharidosis type 2 is a congenital lysosomal disease characterized by iduronate- 
2-sulfatase deficiency, which leads to excessive accumulation of glycosaminoglycans in tis- 
sue. Dysostosis, which primarily involves decreased bone mineralization with morpholog- 
ical changes in the bone, is a major skeletal condition in mucopolysaccharidosis, but its 
pathophysiology is not well known. Here, we report a case of mucopolysaccharidosis type 
2 diagnosed at the age of 2 years with longitudinal follow-up data for more than 15 years. 
Although the patient underwent bone marrow transplantation, the developmental quotient 
did not improve, and cranial hyperostosis progressed prominently with a faintly dilated 
perivascular space. Other dysostoses and contraction of the joints were observed but did 
not improve either. 
© 2021 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Mucopolysaccharidosis (MPS) type 2 or Hunter syndrome is
an X-linked recessive lysosomal disease characterized by de-
ficiency of iduronate-2-sulfatase, which leads to excessive
accumulation of glycosaminoglycans (GAGs) such as der-
matan sulfate (DS) and heparan sulfate (HS) in tissue [1–4] .✩ Acknowledgments: This work was supported by the Japan Society 
grant no. 20K08136 (T.S.). 
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CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4MPS can affect various organs, especially the central ner-
vous system and skeletal system. In addition, it may cause
hepatosplenomegaly, retinal degeneration, corneal opacity,
obstructive pulmonary disorder, and vulvar disease [5] . On the
basis of GAG overaccumulation, symptoms may be classified
as follows: (1) symptoms caused by overaccumulation of GAGs
itself, such as hepatosplenomegaly and corneal opacity, and
(2) those caused by interference of the excessive GAGs withfor the Promotion of Science Grant-in-Aid for Scientific Research 
niversity of Washington. This is an open access article under the 
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Fig 1 – Axial T2-weighted imaging at (A) 6 years and (B) 12 
years of age showing progressive cranial hyperostosis 
(arrows) and worsened cerebral atrophy with faintly dilated 
perivascular spaces (arrowheads). 
 
 
 
 
 
 
 
the metabolism of glycosylation as well as the collagen in the
cytoplasm and extracellular matrix. 
The major skeletal finding in MPS can be characterized
as dysostosis, which primarily involves bone mineralization,
thickened bone, and skeletal deformity [6 ,7] . However, the
relationship between enzyme deficiency and dysostosis
remains unknown. Here, we report a case of iduronate-2-
sulfatase deficiency that presented with disproportionally
worsened cranial hyperostosis after bone marrow transplan-
tation and review the skeletal findings while focusing on the
pathophysiology of the enzymatic deficiency. 
Case report 
A 2-year-old boy with a history of overgrowth ( + 1.5 SD in
height), mild macrocephaly, and recurrent inguinal hernia was
brought to our hospital. His birth weight was 3.512 kg, height
was 51.5 cm, head circumference was 34.2 cm, and chest cir-
cumference was 33.0 cm at 40 weeks of gestation. His devel-
opment quotient score was 56. He showed facial deformity,
saddle nose, and mild limitations in the range of motion in
multiple joints, but no hepatosplenomegaly. His brother had
been diagnosed with Hunter syndrome and had died as a re-
sult of complications of bone marrow transplantation. 
His urinary test revealed elevated DS and HS levels.
Iduronate-2-sulfatase activity was undetectable, which was
diagnostic for MPS type 2. Subsequently, he underwent allo-
geneic bone marrow transplantation with mild normocytic
normochromic anemia for 3 months; his hemoglobin level
ranged from 10 to 13 g/dL. His iduronate-2-sulfatase activity
subsequently improved within normal limits. 
The patient developed mitral valvular regurgitation at 3
years of age, and was repeatedly hospitalized for the treat-
ment of cardiovascular conditions and evaluation of develop-
ment and skeletal rehabilitation. Brain MRI showed no appar-
ent abnormality at 6 years of age ( Fig. 1 A). At the age of 12
years, his height was 134.4 cm (-2.5 SD), and progression of
multiple joint contractures was noted. The development quo-
tient was 36, which was equivalent to that at the age of 17
months. Follow-up brain MRI revealed progressive cranial hy-
perostosis and mild brain atrophy with mildly dilated perivas-
cular spaces at the age of 12 years ( Fig. 1 B). Chest radiogra-
phy showed bilateral hypertrophy in the ribs and clavicles at
the age of 9 years ( Fig. 2 A), which had not changed in size
for 8 years ( Fig. 2 B: at 17 years of age). A bilateral hand radio-
graph obtained at 12 years of age showed decreased bone den-
sity, delayed carpal ossification, short distal phalanges, and
proximal pointing of the metacarpals ( Fig. 3 ). At 16 years of
age, an anterior–posterior pelvic radiograph revealed scolio-
sis, coxa valga, acetabular dysplasia, and widened iliac wings
( Fig. 4 A). Lateral lumbar radiography showed posterior scal-
loping, lower lumbar dislocation, and a fan-shaped deformity
( Fig. 4 B). 
The patient was admitted to the hospital for evaluation
of aortic regurgitation at the ages of 14 and 15. The exami-
nation revealed cardiac function was stable. However, he was
followed up at an outpatient clinic with unchanged joint con-
tracture, bone deformities, and mental status.  Discussion 
The patient in the present case presented with overgrowth
in the early stage, but eventually showed short stature,
disproportional progression of hyperostosis in the cranium
in comparison with the axial skeleton, and severe mental
retardation, which did not improve after bone marrow trans-
plantation. The patient also developed dysostoses with degen-
eration of the spine and hip joints and valvular insufficiency.
GAG metabolism plays an important role in the CNS, skeletal
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Fig. 2 – (A) A chest radiograph showing bilateral 
hypertrophy in the ribs and clavicles at 9 years of age. (B) A 
follow-up chest radiograph at 17 years of age showing that 
the findings did not progress. 
Fig. 3 – A hand radiograph at 12 years of age showing 
decreased bone density, delayed carpal ossification, and 
proximal pointing of the metacarpals. 
Fig. 4 – (A) An anterior-posterior pelvic radiograph at 16 
years of age showing scoliosis, coxa valga, acetabular 
dysplasia with deformity of femoral head (arrows), and 
widened iliac wings. (B) A lateral lumbar radiograph at 16 
years of age showing dislocation of the lower lumbar and a 
fan-shaped deformity (arrows). 
 
 
 
 
 
 
 
 
 
system, and cardiovascular system. Even though bone mar-
row transplantation was performed as soon as possible after
birth, the brain and skeletal damage have not improved [8 ,9] . 
MPS is usually known to cause a short stature [10 ,11] . Patel
et al. demonstrated that patients with MPS type 2 presented
with overgrowth for the first several years and finally showed
a short stature because the growth rate had decreased from 1
year of age [11] . Overgrowth in the first several years can also
be observed in other types of MPS [12 ,13] . The mechanism un-
derlying this finding is still unknown, but it may involve the
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interaction of DS with fibroblast growth factors or other types
of growth factors [14] . Furthermore, overaccumulation of DS
and HS could affect the quality of cartilage and bone as well
as collagen [15–18] . As a result, the fragile ligamentous tissue
and osteochondral tissue might not be able to tolerate weight
gain with growth, eventually resulting in a short stature. 
Iduronate-2-sulfatase deficiency leads to the accumulation
of GAGs (DS and HS) in the lysosome. Excessive GAGs can grad-
ually accumulate in joints, ligaments, and cartilage, leading to
constriction of joints and deformities [5 ,19 ,20] . In oncology, de-
creased activity of iduronate-2-sulfatase has been identified
as one of the mechanisms underlying breast cancer metas-
tasis [21 ,22] . Increased levels of DS can affect not only type 1
collagen in the extracellular matrix but also the cellular struc-
ture [21 ,22] . GAGs, including glucuronic acid or sulfate, have
a highly negative charge and might have the potential to in-
teract with surrounding proteins, such as decorin or collagen
[14] . Excessive GAGs can also interact with collagen compo-
nents through lysyl oxidase, which catalyzes pyridinoline for
collagen cross-linking [23 ,24] . Increased levels of lysyl oxidase
or lysyl oxidase-like proteins can promote metastasis and tu-
mor progression, deteriorating the quality of the extracellular
matrix, especially collagen, which plays an important role as
a barrier [25–28] . 
Excessive GAGs can also interfere cathepsins, a family of
proteases with each type located in a specific tissue [29] . For
the skeletal system, cathepsin K plays an important role in de-
grading collagen and cartilage in osteoclasts [17 ,18] . Decreased
cathepsin K functioning can induce abnormal bone remodel-
ing, leading to bone fragility and finally resulting in dysos-
tosis [17 ,18] . In the cardiovascular areas, in addition to the
GAG deposition in tissues, MPS showed an abnormality in the
turnover of collagen and elastin [15 ,16] and induced overex-
pression of cathepsin B in the fibroblasts of the heart, vascu-
lar wall, and valves, which can lead to degradation of colla-
gen and elastin even in the extracellular matrix [30] . Although
cardiovascular events could be fatal in MPS, enzyme replace-
ment treatment with optimal administration might improve
the prognosis [31 ,32] . 
The dysostosis multiplex group for cranial bones and spine
in MPS is based on an abnormal ossification process with sec-
ondary degeneration, especially in the spine [6] . In MPS, the
skull may be enlarged or dolichocephalic, showing premature
closure of the sutures, underdeveloped mastoid or sinuses, J-
shaped sella turcica, thickened dura, and cranial hyperosto-
sis [6 ,33] . Defective development of the anterosuperior portion
of the vertebrae, scalloping of the vertebrae, instability of the
spine, and scoliosis or kyphosis were observed in the spine
[5 ,6] . With age, secondary degenerative changes might develop
in the loaded joints, such as lumbar or hip joints, probably due
to the fragility of the surrounding ligaments and tendons. The
spinal instability might lead to secondary spinal stenosis or
spinal compression [5] . 
Other features of this condition include osteopenia and an
imbalance in bone thickening with joint contracture or dislo-
cation. Patients may show thickened ribs and clavicles in the
axial skeleton [6] , and the findings for the hands include dif-
fuse decreased bone density, cortical thinning, ballet-shaped
phalanges, proximal pointing of the metacarpals, or delayed
ossification in the carpal bones [6 ,7] . Coxa valga is congeni-tally observed in the femoral head, and it might result in con-
striction of the joints and varus deformities [6 ,7] . The presence
of coxa valga after birth in MPS might imply incomplete col-
lagenogenesis, which also generates fragile collagen. 
In the central nervous system, excessive GAGs can ac-
cumulate in the perivascular space, resulting in a dilated
perivascular space [5] . Disease progression causes delayed
myelination, demyelination, gliosis, and eventual brain atro-
phy [5] . GAGs are a major component of the extracellular ma-
trix in the central nervous system. The heterogeneity or va-
riety of 3-dimensional structures as sites for attachment of
molecules or receptors is well controlled by various enzymes
of glycosylation [34] . Thus, unbalanced amounts of these en-
zymes could lead to morphological or functional changes in
the brain. In patients with MPS, the therapeutic effects of en-
zyme replacement therapy or bone marrow transplant are
limited by the restricted entry of the infused enzymes into
the brain via the blood–brain barrier [20] . Although bone mar-
row transplantation has been shown to prevent the progres-
sion of skeletal features in mice [8] , cranial hyperostosis pro-
gresses disproportionally after bone marrow transplantation
without any progression of skeletal thickness in the ribs and
clavicles. This finding suggests that the cranial hyperostosis
in MPS might not be worsened cranial GAG metabolism but
rather a secondary reaction to severe disturbances in CNS de-
velopment. In this patient, the severe mental retardation did
not improve despite bone marrow transplantation at 2 years
of age. Cranial hyperostosis can develop due to the reduction
of intracranial volume or a severe MPS phenotype [33 ,35] . 
We encountered a case of type 2 MPS showing dispro-
portional progression of skeletal features after bone marrow
transplantation. The deficiency of iduronate-2-sulfatase via
excessive GAGs might have influenced the microenvironment
in the cytoplasm and extracellular matrix, especially the colla-
gen, cartilage, and GAG metabolism in the central nervous sys-
tem and skeletal system. The brain and spinal symptoms and
features of MPS might develop based on abnormal metabolism
of both the central nervous system and skeletal system. 
Patient consent 
We obtained the written informed consent from the patient’s
parents for publication. 
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